Network meta-analysis (NMA) of pembrolizumab for first-line (1L) treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

被引：0
|
作者：
Ramakrishnan, Karthik
Mojebi, Ali
Ayers, Dieter
Chirovsky, Diana Romana
Borse, Rebekah
Keeping, Sam
机构：
[1] Merck & Co Inc, Kenilworth, NJ USA
[2] PRECISIONheor, Vancouver, BC, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18012
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina
    Victoria Wurcel
    Diana Chirovsky
    Rebekah Borse
    Juan Ignacio Altuna
    Fernando Carabajal
    Jyotika Gandhi
    Advances in Therapy, 2021, 38 : 2613 - 2630
  • [32] Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina
    Wurcel, Victoria
    Chirovsky, Diana
    Borse, Rebekah
    Altuna, Juan Ignacio
    Carabajal, Fernando
    Gandhi, Jyotika
    ADVANCES IN THERAPY, 2021, 38 (05) : 2613 - 2630
  • [33] Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States
    Borse, Rebekah H.
    Ramakrishnan, Karthik
    Gandhi, Jyotika
    Dhankhar, Praveen
    Chirovsky, Diana
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 954 - 965
  • [34] Pembrolizumab plus lenvatinib (P plus L) versus alternate therapies in first-line (1L) for advanced renal cell carcinoma (aRCC): A network meta-analysis (NMA).
    Yan, Kevin
    Rane, Pratik
    Schmidinger, Manuela
    Peer, Avivit
    Druyts, Eric
    Burgents, Joseph E.
    Sundaram, Murali
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 422 - 422
  • [35] Real-World Patient Characteristics and Time on Treatment Outcomes Among Patients Receiving First-Line Pembrolizumab in the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the United States
    Wang, L.
    Black, C.
    Ramakrishnan, K.
    Turzhitsky, V.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 112 (05): : E42 - E42
  • [36] Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
    Rischin, Danny
    Harrington, Kevin J.
    Greil, Richard
    Soulieres, Denis
    Tahara, Makoto
    de Castro, Gilberto
    Psyrri, Amanda
    Baste, Neus
    Neupane, Prakash C.
    Bratland, Ase
    Fuereder, Thorsten
    Hughes, Brett Gordon Maxwell
    Mesia, Ricard
    Ngamphaiboon, Nuttapong
    Rordorf, Tamara
    Ishak, Wan Zamaniah Wan
    Zhang, Yayan
    Jin, Fan
    Gumuscu, Burak
    Burtness, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC)
    Sun, Lova
    Cohen, Roger B.
    Colevas, A. Dimitrios
    ORAL ONCOLOGY, 2024, 158
  • [38] Platinum/taxane/pembrolizumab vs Platinum/5-fluorouracil/pembrolizumab in recurrent/metastatic Head and Neck Squamous Cell Carcinoma (r/m HNSCC)
    Sun, L.
    Cohen, R.
    Colevas, A. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E34 - E35
  • [39] A multicenter, retrospective study analysis: Evaluating the efficacy and safety of pembrolizumab in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma.
    Hu, Man
    Zhang, Shichuan
    Han, Yaqian
    Wu, Hui
    Gao, Jin
    Wu, Haijun
    Lin, Qin
    Shang, Wei
    Li, Xia
    Feng, Hong
    Qiao, Qiao
    Hu, Guangyuan
    Yang, Kunyu
    Song, Xicheng
    Cao, Yuandong
    Kang, Min
    Wang, Ruozheng
    Yu, Jinming
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] The observational ENCORE study: Cetuximab plus platinum-based therapy (PBT) for first-line (1L) treatment of patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Le Tourneau, C.
    Ghiani, M.
    Cau, M. C.
    Depenni, R.
    Ronzino, G.
    Livi, L.
    Montesarchio, V.
    Bretagne, M.
    Saint-Ghislain, M.
    Schulten, J.
    Messinger, D.
    Sbrana, A.
    Ghi, M. G.
    ANNALS OF ONCOLOGY, 2017, 28
12345